← Browse by Condition
Medical Condition
esr1 gene mutation
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3
NCT06548919
Recruiting
Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
Enrollment
450 pts
Location
China
Sponsor
SciClone Pharmaceuticals
NCT06382948 Phase 3
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Enrollment
240 pts
Location
Austria, Czechia, Fr...
Sponsor
MedSIR